20/20 HealthCare Partners
  • Home
  • Strategic Partners
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact

20/20 HealthCare Partners

22 Dec2020

Variantyx Licenses IBM Technologies That Leverage AI for Somatic Analysis

Written by 2020HCP.com. Posted in News

Variantyx, the leader in high complexity hereditary disease testing, today announced that it has entered into a licensing agreement with IBM for technologies that leverage artificial intelligence for somatic analysis from which Variantyx intends to develop comprehensive tumor diagnostic solutions.

“Variantyx’s proprietary whole genome sequencing (WGS)-based methodology has transformed genetic testing and personalized medicine for pediatric and adult neurological disorders and rare, undiagnosed diseases,” said Haim Neerman, CEO of Variantyx. “This license agreement will accelerate development of a similarly transformative, cancer diagnostic solution.”

“We are pleased to support Variantyx as they work to advance the use of genomics to help scale precision medicine and meet the growing needs of personalized care,” said Ajay Royyuru, Vice President, Healthcare & Life Sciences Research, IBM.

Latest News

  • Variantyx Licenses IBM Technologies That Leverage AI for Somatic Analysis December 22, 2020
  • Coagulo Medical Technologies Announces $6.5 Million in Financing to Accelerate Delivery of Disruptive Coagulation Diagnostics Platform December 22, 2020
  • SQZ Biotech lines up $75m IPO for cell therapy R&D October 20, 2020
  • Tech Crunch: XR telemedicine platform XRHealth raises $7M April 22, 2020
  • EnClear Therapies Announces $10M Series A Financing February 20, 2020

20/20 HealthCare Partners | 2000 Commonwealth Ave, Suite 200, Auburndale, MA 02466 | Contact Us

Copyright © 2019
  • Home
  • Strategic Partners
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact